Physician
Luo, Lily
Luo, Lily was paid $590K by Medicaid between Jan 2018 and Mar 2023, across 37 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 39% of everything it billed.
33Billing provider infoLUO, LILY
QUINCY, MA 02171
QUINCY, MA 02171
33aNPI1831534205assigned 04/30/2013
33bProvider typePediatrics Physician
28Total paid$590K
24GClaims13,894
24DCodes billed37
24AFirst – last monthJan 2018 – Mar 2023
Compared with peers
Next to other Pediatrics Physician providers in Massachusetts
Rank by total paid#135 of 1,273
Median peer was paid$24K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,586 | $70K | |
| 2019 | 2,242 | $94K | |
| 2020 | 2,426 | $96K | |
| 2021 | 3,248 | $140K | |
| 2022 | 3,755 | $161K | |
| 2023 | 637 | $29K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 39% | 4,021 | 3,321 | $230K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 2,052 | 1,751 | $202K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7.4% | 1,572 | 1,417 | $44K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.3% | 1,487 | 1,474 | $14K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.2% | 550 | 510 | $13K |
| 99051 | 1.8% | 626 | 573 | $10K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.5% | 105 | 105 | $9K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.4% | 822 | 765 | $8K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.3% | 95 | 95 | $8K |
| 99173 | 1.3% | 351 | 350 | $8K | |
| 99401 | <1% | 194 | 191 | $6K | |
| 96127 | <1% | 515 | 515 | $5K |
25 more codes
| 0071A | <1% | 91 | $4K | |
| 0072A | <1% | 81 | $4K | |
| 92552 | <1% | 105 | $3K | |
| 0074A | <1% | 57 | $3K | |
| 90461 | <1% | 65 | $2K | |
| 99188 | <1% | 75 | $2K | |
| 36416 | <1% | 191 | $2K | |
| 99442 | <1% | 88 | $2K | |
| 0082A | <1% | 35 | $2K | |
| 0083A | <1% | 33 | $2K | |
| 0124A | <1% | 25 | $1K | |
| 0081A | <1% | 23 | $1K | |
| 0002A | <1% | 23 | $1K | |
| 0004A | <1% | 18 | $825.84 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 60 | $800.16 |
| 0054A | <1% | 12 | $750.00 | |
| 0001A | <1% | 15 | $688.20 | |
| 0154A | <1% | 12 | $550.56 | |
| 99177 | <1% | 12 | $450.00 | |
| 85018 | <1% | 188 | $423.16 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $305.20 |
| 99000 | <1% | 242 | $242.00 | |
| 94664 | <1% | 12 | $172.56 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $115.00 |
| 92551 | <1% | 12 | $101.16 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.